Walleye Capital’s bluebird bio BLUE Stock Holding History

Walleye Capital’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-16,706	Closed	-$329K	–	5311
2024 Q2	$329K	Sell	16,706 -22,466	-57%	-$450K	﹤0.01%	3898
2024 Q1	$1M	Buy	+39,172	New	+$1M	﹤0.01%	2584
2023 Q3	–	Sell	-41,838	Closed	-$2.75M	–	4894
2023 Q2	$2.75M	Buy	+41,838	New	+$3.06M	0.01%	1108
2022 Q4	–	Sell	-3,165	Closed	-$401K	–	3194
2022 Q3	$401K	Buy	+3,165	New	+$358K	0.01%	1618
2022 Q2	–	Sell	-6,486	Closed	-$629K	–	2375
2022 Q1	$629K	Buy	6,486 +5,981	+1,184%	+$789K	0.02%	901
2021 Q4	$101K	Sell	505 -2,448	-83%	-$578K	﹤0.01%	1684
2021 Q3	$731	Buy	2,953 +2,297	+350%	+$657K	0.02%	601
2021 Q2	$272	Buy	+656	New	+$260K	0.01%	977
2019 Q4	–	Sell	-283	Closed	-$308K	–	1801
2019 Q3	$337K	Buy	+283	New	+$432K	0.02%	929

Other funds holding BLUE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Walleye Capital's BLUE Position: Q3 2024 in Review

Walleye Capital sold out of bluebird bio (BLUE) in Q3 2024, closing a stake of 16,706 shares — an estimated $329K sold.

Walleye Capital first reported a position in BLUE in Q3 2019 and held it in 9 quarters. The position peaked at $2.75M in Q2 2023. 140 funds tracked by Wall St. Rank hold BLUE as of Q3 2024.

Walleye Capital reported no remaining bluebird bio position as of Q3 2024 after selling out during the quarter.
Walleye Capital sold 16,706 bluebird bio shares in Q3 2024, an estimated $329K.
Walleye Capital first reported a position in bluebird bio in Q3 2019 and held it in 9 quarters.
Walleye Capital's bluebird bio position peaked at $2.75M in Q2 2023.
140 funds tracked by Wall St. Rank held bluebird bio as of Q3 2024.

Based on Walleye Capital's 13F filing for Q3 2024, filed 14 Nov 2024.